Bayers-finerenone-meets-primary-endpoint-Phase-III-FIGARO-DKD-cardiovascular-outcomes-study-patients

Finerenone significantly reduced the composite primary endpoint of cardiovascular death and non-fatal cardiovascular events versus placebo when added to standard of care / Following the FIDELIO-DKD study, FIGARO-DKD is the second positive Phase III study within the finerenone study program in chronic kidney disease (CKD) and type 2 diabetes (T2D) to meet its primary endpoint / Patients with CKD and T2D are three times more likely to die from a cardiovascular-related cause than those with type 2 diabetes alone / Based on the comprehensive finerenone clinical trial program, finerenone is the first investigational non-steroidal, selective mineralocorticoid receptor (MR) antagonist to demonstrate renal and cardiovascular benefits in patients with chronic kidney disease and type 2 diabetes
Source: Bayer Company News - Category: Pharmaceuticals Source Type: news